Therapeutic approaches to target caSTAT5 are being studied, like the small molecule bromodomain inhibitor JQ1, which reduces STAT5 function in leukemia and lymphoma cells with caSTAT5 (103). This evidence concerns the gene STAT5A and leukemia.